VIDEO: Pegcetacoplan shows positive 2-year results in geographic atrophy reduction
Click Here to Manage Email Alerts
In this Healio Video Perspective, Rishi P. Singh, MD, discusses his presentation from the Retina Society meeting covering the 24-month data investigating pegcetacoplan for the treatment of geographic atrophy.
“What this study was able to show in both OAKS and DERBY over a 2-year period was that there was a significant reduction in geographic atrophy growth and progression,” he said. “What was particularly important was seeing that in the last 6 months of the trial, there was an increased reduction and effect of this drug over that period of time.”
Collapse
Singh RP. Safety of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the DERBY and OAKS phase 3 trials. Presented at: Retina Society meeting; Nov. 2-5, 2022; Pasadena, California.
Read more about
Click Here to Manage Email Alerts